Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
SchizophreniaMetabolic Syndrome XInsulin Resistance
Interventions
DRUG

Switch

Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.

DRUG

Control

Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.

Trial Locations (1)

92161

VA San Diego Healthcare System, San Diego

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Pfizer

INDUSTRY

lead

Veterans Medical Research Foundation

OTHER